CGEM cullinanoncology.com Net earnings per share growth forecast for next year

Corporate company logo of Cullinan Corp (CGEM)

Cullinan Therapeutics (CGEM) is recognized as an expert in precision oncology, developing high-precision methods for combating tumors. The company actively acquires promising molecules, integrating new platforms into its R&D processes. The primary drivers are the drug CLN-978 for autoimmune therapy and a substantial liquidity reserve. The projected growth of earnings per share for year n+1 demonstrates the issuer's resilience, while the 30.60 level captures the current state.

CGEM: Cullinan Oncology Net earnings per one share growth forecast for next year 07/04/2022 - 11/17/2026

Financial and market metric breakdowns for Cullinan Therapeutics, Inc. (CGEM)

- share price and consensus valuation forecast:
Fundamental company analysis:Cullinan Therapeutics, Inc., CGEM
Brand item of cullinanoncology.com

To assess the asset quality of Cullinan Therapeutics (CGEM), it is critical to track the consensus forecasts of the professional community. By analyzing the outlook for EPS changes next year, an investor can see the aggregated trend of expected net income per share, which is adjusted daily. For a biotech company utilizing AI-driven molecule design, this indicator reflects market confidence in the accelerated commercialization of drugs. A positive trend confirms the effectiveness of the innovative development model and the growth of capital value.

Competing companies

GMAB (Genmab Corp) - Earnings growth forecast for next year|Earnings growth forecast for next year exelixis.com|Net earnings per share growth forecast for next year Nuvalent (NUVL)|KYMR (Kymera) - Expected earnings per share trend next year|Earnings growth forecast for next year IDYA (IDEAYA Biosciences Inc)|Net earnings per one share growth forecast for next year Enliven Pharma|ORIC Pharmaceuticals Inc - Earnings growth forecast for next year|Expected net earnings per share growth next year Relay Therapeutics, Inc.|NRIX (Nurix Therapeutics) - Expected earnings per share growth for next year|TYRA: Projected earnings per share increase next year|VSTM (verastem.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year Monte Rosa Tx GLUE|Earnings growth forecast for next year IMRX|C4 Therapeutics - Projected earnings per share growth rate for next year|Black Diamond Therapeutics - Expected earnings per share growth for next year|Expected earnings per share trend next year RPTX|PMVP: Expected earnings per share growth for next year|karyopharm.com - Projected earnings per share increase next year|PPCB: Earnings growth forecast for next year|Bio Green Med Solution Inc - Expected earnings per share trend next year|AADI (Aadi Bioscience Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year aileronrx.com ALRN|Net earnings per share growth forecast for next year Blueprint Medicines Corp. (BPMC)|GLYC (GlycoMimetics) - Expected earnings per share trend next year|Earnings growth forecast for next year SWTX (SpringWorks Therapeutics, Inc)